https://de.marketscreener.com/kurs/aktie/REVIVE-THERAPEUTICS-LTD-62465380/news/Revive-Therapeutics-Ltd-gibt-Update-zur-klinischen-Phase-3-Studie-fur-Bucillamin-in-COVID-19-41085196/?utm_source=telegram&utm_medium=social&utm_campaign=share